PET-CT Imaging in Breast Cancer Patients: New Tracers, Future Directions
- *Corresponding Author:
- Tímea Tokés M.D
Department of Internal Medicine
Oncology Division Semmelweis University
Faculty of Medicine, Budapest, Hungary
E-mail: [email protected]
Received date: June 27, 2013; Accepted date: July 23, 2013; Published date: July 28, 2013
Citation: Tokés T, Kajáry K, Torgyík L, Lengyel Z, Györke T, et al. (2013) PET-CT Imaging in Breast Cancer Patients: New Tracers, Future Directions. J Mol Imaging Dynam 3:111. doi:10.4172/2155-9937.1000111
Copyright: © 2013 Tokés T, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Positron Emission Tomography using 18F-fluoro-deoxi-glucose (FDG-PET) is giving a new perspective in disease staging and therapeutic response evaluation in daily oncological practice. To understand better the biological behavior and therapeutic response of breast cancer, new tracers and targets of molecular imaging are under investigation.These tracers may lead to non-invasive evaluation of the main, leading therapeutic decision-maker properties of metastatic breast cancer such as receptor status, proliferation activity and therapy resistance, and could also become predictive markers in the early measurement of therapeutic response in the neoadjuvant treatment of locally advanced breast cancer. However, these new agents are currently not available in the daily practice; the preliminary results are promising.